Literature DB >> 29777711

UCA1 confers paclitaxel resistance to ovarian cancer through miR-129/ABCB1 axis.

Junrong Wang1, Cong Ye2, Junbao Liu3, Yubo Hu1.   

Abstract

Increasing evidence has demonstrated the involvement of dysregulated long non-coding RNAs (lncRNAs) in chemoresistance acting as potential oncogenes or tumor suppressors in various cancers. Nevertheless, the profound molecular mechanisms of lncRNAs in ovarian cancer (OC) chemoresistance is not well elucidated. The objective of this work was to investigate the role and molecular mechanisms of urothelial carcinoma associated 1 (UCA1) in paclitaxel (PTX) resistance in OC. Our results indicated that UCA1 was significantly up-regulated in PTX-resistant OC cells (SKOV3/PTX and HeyA-8/PTX) compared with their parental cells (SKOV3 and HeyA-8). Functionally, UCA1 knockdown sensitized SKOV3/PTX and HeyA-8/PTX cells to PTX through enhancing PTX-induced apoptosis. Mechanistically, UCA1 silencing induced PTX sensitivity of SKOV3/PTX and HeyA-8/PTX cells by de-repressing ABCB1 through sponging miR-129. Collectively, our study elaborated a novel UCA1/miR-129/ABCB1 regulatory axis underlying PTX resistance of OC cells, providing a potential therapeutic target for OC.
Copyright © 2018 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  ABCB1; Ovarian cancer; Paclitaxel resistance; UCA1; miR-129

Mesh:

Substances:

Year:  2018        PMID: 29777711     DOI: 10.1016/j.bbrc.2018.05.104

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  26 in total

1.  Long non-coding RNAs in ovarian cancer: expression profile and functional spectrum.

Authors:  Selin Oncul; Paola Amero; Cristian Rodriguez-Aguayo; George A Calin; Anil K Sood; Gabriel Lopez-Berestein
Journal:  RNA Biol       Date:  2019-12-17       Impact factor: 4.652

Review 2.  Non-Coding RNAs in Endometrial Physiopathology.

Authors:  Alessandro La Ferlita; Rosalia Battaglia; Francesca Andronico; Salvatore Caruso; Antonio Cianci; Michele Purrello; Cinzia Di Pietro
Journal:  Int J Mol Sci       Date:  2018-07-20       Impact factor: 5.923

3.  Expression Analysis of lncRNAs in Refractory and Non-Refractory Epileptic Patients.

Authors:  Sara Mirzajani; Soudeh Ghafouri-Fard; Jafar Mehvari Habibabadi; Shahram Arsang-Jang; Mir Davood Omrani; Seyed Sohrab Hashemi Fesharaki; Arezou Sayad; Mohammad Taheri
Journal:  J Mol Neurosci       Date:  2020-01-03       Impact factor: 3.444

4.  LncRNA UCA1 elevates the resistance of human leukemia cells to daunorubicin by the PI3K/AKT pathway via sponging miR-613.

Authors:  Qiying Yao; Li Zhang; Yuchuan Wang; Junli Liu; Liu Yang; Yingjie Wang
Journal:  Biosci Rep       Date:  2021-06-25       Impact factor: 3.840

Review 5.  The prognostic value and mechanisms of lncRNA UCA1 in human cancer.

Authors:  Fei Yao; Qiang Wang; Qingming Wu
Journal:  Cancer Manag Res       Date:  2019-08-14       Impact factor: 3.989

6.  BRAF/EZH2 Signaling Represses miR-129-5p Inhibition of SOX4 Thereby Modulating BRAFi Resistance in Melanoma.

Authors:  Kathleen Gebhardt; Bayram Edemir; Elisabeth Groß; Linda Nemetschke; Stefanie Kewitz-Hempel; Rose K C Moritz; Cord Sunderkötter; Dennis Gerloff
Journal:  Cancers (Basel)       Date:  2021-05-15       Impact factor: 6.639

Review 7.  Role of microRNA-129 in cancer and non-cancerous diseases (Review).

Authors:  Bingpeng Deng; Xuan Tang; Yong Wang
Journal:  Exp Ther Med       Date:  2021-06-30       Impact factor: 2.447

Review 8.  The Role of lncRNAs in the Stem Phenotype of Pancreatic Ductal Adenocarcinoma.

Authors:  Jorge Melendez-Zajgla; Vilma Maldonado
Journal:  Int J Mol Sci       Date:  2021-06-15       Impact factor: 5.923

Review 9.  Epigenetic Regulation by lncRNAs: An Overview Focused on UCA1 in Colorectal Cancer.

Authors:  Bernadette Neve; Nicolas Jonckheere; Audrey Vincent; Isabelle Van Seuningen
Journal:  Cancers (Basel)       Date:  2018-11-14       Impact factor: 6.639

10.  Shikonin suppresses NEAT1 and Akt signaling in treating paclitaxel-resistant non-small cell of lung cancer.

Authors:  Farong Zang; Yuanquan Rao; Xinhai Zhu; Zhibing Wu; Hao Jiang
Journal:  Mol Med       Date:  2020-04-08       Impact factor: 6.354

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.